Clinical trial · Observational
CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma
Clinical Study on CXCR4 PET/MRI Targeted Integrated Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma
NCT06234319CI-TRIAL-00074674unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project intends to evaluate the role of C-X-C chemokine receptor type 4 (CXCR4) targeted PET/MRI integrated imaging in the grading and molecular typing of brain gliomas, using primary glioma patients as the research subjects and post-operative histopathological analysis as the reference, and to establish an evaluation model for the prognosis of primary glioma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CXCR4 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Standardised uptake values
- timeFrame
- completed within one week after the PET/MRI examination
- description
- Standardised uptake values of suspected glioma disease in CXCR4 PET/MRI imaging
- measure
- expression of CD34
- timeFrame
- completed within one week after surgery
- description
- Immunohistochemical evaluation of the expression of CD34 in postoperative tumor tissue
- measure
- expression of CXCR4
- timeFrame
- completed within one week after surgery
- description
- Immunohistochemical evaluation of the expression of CXCR4 in postoperative tumor tissue
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed with primary glioma based on clinical, imaging, and histopathological criteria; 2. The patient is at least 18 years old; 3. Participate in CXCR4 PET/MRI imaging within 15 days before surgery; 4. Surgical resection of glioma lesion tissue can be used for pathological analysis; 5. The patient voluntarily participates and signs the informed consent form. Exclusion Criteria: 1. Pregnant or breastfeeding patients; 2. The image quality of the imaging is poor and cannot be used for diagnosis and evaluation; 3. Molecular typing was not determined by histologic examination; 4. patients with claustrophobia; 5. Patients who are allergic to radioactive tracers and MRI contrast agents, and patients with renal insufficiency.
References
Publications (1)
- RESULTJacobs SM, Wesseling P, de Keizer B, Tolboom N, Ververs FFT, Krijger GC, Westerman BA, Snijders TJ, Robe PA, van der Kolk AG. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):481-491. doi: 10.1007/s00259-021-05196-4. Epub 2021 Feb 7. PMID 33550492